medigraphic.com
ISSN 2078-7170 (Electronic)

2013, Number 2

<< Back Next >>

CorSalud 2013; 5 (2)

Left ventricular dysfunction in patients with human immunodeficiency virus infection

Valdés MA, Reyes PAM

Language: Spanish
References: 51
Page: 189-197
PDF size: 362.86 Kb.


ABSTRACT

Infection with the human immunodeficiency virus is a major cause of acquired heart disease, especially symptomatic left ventricular dysfunction. A literature review was conducted to deepen the understanding of the various clinical, pathophysiological and diagnostic aspects that characterize these patients. The pathogenesis of left ventricular dysfunction is related to various causative agents such as: myocardial infection by the virus itself, opportunistic infections or by other viruses, autoimmune mechanisms, nutritional deficiencies, overexpression of cytokines and drug induced toxicity. Symptomatic systolic dysfunction is a late manifestation of cardiac involvement, while a significant proportion of patients have clinically silent abnormalities. Diastolic dysfunction presents with early alterations in myocardial relaxation and in left ventricular filling dynamics. Echocardiography is useful for its diagnosis. Current antiretroviral therapy increases the survival of patients infected with human immunodeficiency virus, which presumably would lead to an increase in the prevalence of cardiac complications. New prospective observational studies to determine the susceptibility of developing symptomatic heart disease in patients infected with this virus are required.


REFERENCES

  1. Anglaret X. Global AIDS epidemic: from epide-miology to universal treatment. Rev Med Interne. 2008;29 Suppl 3:S269-73.

  2. Alonso-Villaverde Lozano C. Physiopathology of cardiovascular disease in HIV-infected patients. Enferm Infecc Microbiol Clin. 2009;27 Suppl 1:33-9.

  3. MacNeil A, Sarr AD, Sankalé JL, Meloni ST, Mboup S, Kanki P. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 Infection. J Virol. 2007;81(10):5325-30.

  4. Boccara F. Cardiovascular complications and athe-rosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS. 2008;22 Suppl 3:S19-26.

  5. El Hattaoui M, Charei N, Boumzebra D, Aajly L, Fadouach S. Prevalence of cardiomyopathy in HIV infection: prospective study on 158 HIV patients. Med Mal Infect. 2008;38(7):387-91.

  6. Chan PA, Wakeman SE, Flanigan T, Cu-Uvin S, Kojic E, Kantor R. HIV-2 diagnosis and quantification in high-risk patients. AIDS Res Ther. 2008;5:18.

  7. Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, Lin CC, et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM. 2007; 100(2):97-105.

  8. Hogg R, Lima V, Sterne JA, Grabar S, Battegay M, Bonarek M, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293-9.

  9. Bernardino de la Serna JI, Arribas López JR. Contro-versies and future of the approach to cardio-vascular disease in HIV patients. Enferm Infecc Microbiol Clin. 2009;27 Suppl 1:48-53.

  10. 10.Barelli S, Angelillo-Scherrer A, Foguena AK, Periard D, Cavassini M. Controversies regarding the patho-genesis of cardiovascular diseases in HIV patients. Rev Med Suisse. 2011;7(292):905-10.

  11. 11.Rogers JS, Zakaria S, Thom KA, Flammer KM, Kanno M, Mehra MR. Immune reconstitution inflammatory syndrome and human immunodeficiency virus-associated myocarditis. Mayo Clin Proc. 2008; 83(11):1275-9.

  12. 12.Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118(6):639-48.

  13. 13.Huang CH, Vallejo JG, Kollias G, Mann DL. Role of the innate immune system in acute viral myocardi-tis. Basic Res Cardiol. 2009;104(3):228-37.

  14. 14.Kyto V, Saraste A, Voipio-Pulkki LM, Saukko P. Inci-dence of fatal myocarditis: a population-based study in Finland. Am J Epidemiol. 2007; 165(5):570-4.

  15. 15.Elamm C, Fairweather D, Cooper LT. Republished: Pathogenesis and diagnosis of myocarditis. Post-grad Med J. 2012;88(1043):539-44.

  16. 16.Uriel N, Jorde UP, Cotarlan V, Colombo PC, Farr M, Restaino SW, et al. Heart transplantation in human immunodeficiency virus-positive patients. J Heart Lung Transplant. 2009;28(7):667-9.

  17. 17.Thorin E, Clozel M. The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol. 2010;60:1-26.

  18. 18.Habib S, Ali A. Biochemistry of nitric oxide. Indian J Clin Biochem. 2011;26(1):3-17.

  19. 19.Avelino-Silva VI, Ho YL, Avelino-Silva TJ, Santos S de S. Aging and HIV infection. Ageing Res Rev. 2011;10 (1):163-72.

  20. 20.Hruz PW, Yan Q, Struthers H, Jay PY. HIV protease inhibitors that block GLUT4 precipitate acute, de-compensated heart failure in a mouse model of dilated cardiomyopathy. FASEB J. 2008;22(7):2161-7.

  21. 21.Capel E, Auclair M, Caron-Debarle M, Capeau J. Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sen-sitivity in murine and human adipocytes. Antivir Ther. 2012;17(3):549-56.

  22. 22.Boger MS, Shintani A, Redhage LA, Mitchell V, Haas DW, Morrow JD, et al. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr. 2009;52(4):480-7.

  23. 23.Arribas JR. Drugs in traditional drug classes (nucleo-side reverse transcriptase inhibitor / nonnucleoside reverse transcriptase inhibitor / protease inhibi-tors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).Curr Opin HIV AIDS. 2009;4(6):507-12.

  24. 24.Taiwo B, Murphy RL, Katlama C. Novel antiretro-viral combinations in treatment-experienced pat-ients with HIV infection: rationale and results. Drugs. 2010;70(13):1640-42.

  25. 25.Mayosi BM. Contemporary trends in the epide-miology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart. 2007; 93(10):1176-83.

  26. 26.Cowie MR. Recent developments in the manage-ment of heart failure. Practitioner. 2012;256(1752): 25-9, 3.

  27. 27.El Amari EB, Hirschel B. HIV-AIDS 2008: the year in review. Rev Med Suisse. 2009;5(185):69-71.

  28. 28.Okoromah CA, Ojo OO, Ogunkunle OO. Cardiovas-cular dysfunction in HIV-infected children in a sub-Saharan African country: Comparative Cross-sectional observational study. J Trop Pediatr. 2012; 58(1):3-11.

  29. 29.Lot F. Epidemiology of HIV/AIDS and other sexually transmitted diseases in women. Med Sci (Paris). 2008;24(2):7-19.

  30. 30.Sani MU. Myocardial disease in human immuno-deficiency virus (HIV) infection: a review. Wien Klin Wochenschr. 2008;120(3-4):77-87.

  31. 31.Binkley PF, Lesinski A, Ferguson J, Hatton PS, Yamo-koski L, Hardikar S, et al. Recovery of normal ventri-cular function in patients with dilated cardiomyo-pathy: predictors of an increasingly prevalent cli-nical event. Am Heart J. 2008;155(1):69-74.

  32. 32.Mizuno H, Ohte N, Wakami K, Narita H, Fukuta H, Asada K, et al. Peak mitral annular velocity during early diastole and propagation velocity of early diastolic filling flow are not interchangeable as the parameters of left ventricular early diastolic func-tion. Am J Cardiol. 2008;101(10):1467-71.

  33. 33.Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV Infection in Denmark, 1995–2005. Ann Inter Med. 2007;16;146(2):87-95.

  34. 34.Fetzer BC, Hosseinipour MC, Kamthuzi P, Hyde L, Bramson B, Jobarteh K, et al. Predictors for mor-tality and loss to follow-up among children receiving anti-retroviral therapy in Lilongwe, Trop Med Int Health. 2009;14(8):862-9.

  35. 35.Luers C, Maisch B. Echocardiography: future de-velopments. What is diastole and how to assess it? Impaired left ventricular systolic function. Minerva Cardioangiol. 2011;59(4):331-47.

  36. 36.Borbély A, Papp Z, Edes I, Paulus WJ. Review Mole-cular determinants of heart failure with normal left ventricular ejection fraction. Pharmacol Rep. 2009; 61(1):139-45.

  37. 37.Rovner A, Waggoner AD, Mathews SJ, Dávila-Ro-mán VG, de las Fuentes L. Role of tissue Doppler and color M-mode imaging for evaluation of dias-tolic function in ambulatory patients with LV systolic dysfunction. Echocardiography. 2007;24(5): 478-84.

  38. 38.Stewart KC, Kumar R, Charonko JJ, Ohara T, Vlachos PP, Little WC. Evaluation of LV diastolic function from color M-mode echocardiography. JACC Car-diovasc Imaging. 2011;4(1):37-46.

  39. 39.Reinsch N, Kahlert P, Esser S, Sundermeyer A, Neuhaus K, Brockmeyer N, et al. Echocardiographic findings and abnormalities in HIV-infected patients: results from a large, prospective, multicenter HIV-heart study. Am J Cardiovasc Dis. 2011;1(2):176-84.

  40. 40.Previtali M, Chieffo E, Ferrario M, Klersy C. Echo-cardiographic evaluation of left ventricular diastolic function: correlation between echocardiographic and hemodynamic parameters. Minerva Cardioan-giol. 2007;55(6):733-40.

  41. 41.Kheradvar A, Gharib M. On mitral valve dynamics and its connection to early diastolic flow. Ann Bio-med Eng. 2009; 37(1):1-13.

  42. 42.Little WC, Oh JK. Echocardiographic evaluation of diastolic function can be used to guide clinical care. Circulation. 2009;120(9):802-9.

  43. 43.Aljaroudi W, Alraies MC, Halley C, Rodríguez L, Grim RA, Thomas JD, et al. Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction. Circulation. 2012;125(6): 782-8.

  44. 44.Hogg R, Lima V, Sterne JA, Grabar S, Battegay M, Bonarek M, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372(9635):293-9.

  45. 45.Goland S, Czer LS, Siegel RJ, Tabak S, Jordan S, Luthringer D, et al. Intravenous immunoglobulin treatment for acute fulminant inflammatory cardio-myopathy: Series of six patients and review of literature. Can J Cardiol. 2008; 24(7): 571–574.

  46. 46.Kramer AS, Lazzarotto AR, Sprinz E, Manfroi WC. Metabolic abnormalities, antiretroviral therapy and cardiovascular disease in elderly patients with HIV. Arq Bras Cardiol. 2009; 93(5):561-8.

  47. 47.Susan-Resiga D, Bentley AT, Lynx MD, LaClair DD, McKee EE. Zidovudine inhibits thymidine phos-phorylation in the isolated perfused rat heart. Anti-microb Agents Chemother. 2007; 51(4):1142-9.

  48. 48.Braithwaite RS, Kozal MJ, Chang CC, et al. Ad-herence, virological and immunological outcomes for HIV-infected veterans starting combination anti-retroviral therapies. AIDS. 2007; 21:1579–89.

  49. 49.Von Hentig N. Lopinavir/ritonavir: appraisal of its use in HIV therapy. Drugs Today. 2007; 43(4):221-47.

  50. 50.Cossarini F, Salpietro S, Galli L, Gianotti N, Nozza S, Spagnuolo V et al. Monotherapy with atazanavir as a simplification strategy: results from an observa-tional study. Acquir Immune Defic Syndr. 2012; 60(3):101-3.

  51. 51.Boufassa F, Goujard C, Viard JP, Carlier R, Lefebvre B, Yeni P, et al. Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort. Antivir Ther. 2012;17(1):91-100.




2020     |     www.medigraphic.com